• EGCG Nanoparticles Enhance FLASH Radiotherapy

  2026-10-01

  This study reports functionalized, self-assembled EGCG nanoparticles, termed BENPs, as a radiosensitizing strategy for improving FLASH radiotherapy. In a 4T1 tumor model, BENPs enhanced radiation-associated oxidative and DNA damage, promoted tumor-cell death, and reshaped antitumor immune responses while maintaining the reported biosafety profile.

• Q-VD-OPh: Pan-Caspase Inhibitor Guide

  2026-10-01

  Q-VD-OPh is a cell-permeable, irreversible pan-caspase inhibitor for apoptosis research and caspase activity inhibition. Product data support its use in mechanistic cell-death assays, cryopreservation workflows, and selected Alzheimer’s disease research models, with important limits on interpretation and dosing.

• BV6 IAP Antagonist for Apoptosis Workflows

  2026-09-30

  BV6 is a Smac-mimetic IAP antagonist for testing apoptosis induction, radiotherapy response, chemotherapy sensitization, and immune-cell cytotoxicity in cancer models. This practical guide connects dose-response design with orthogonal pathway assays, combination scheduling, model-specific controls, and evidence-aware interpretation.

• Making RA Mechanisms Visible with Cy3 Secondary

  2026-09-30

  A translational strategy for using Cy3 fluorescence to connect NF-κB and NLRP3 biology with reproducible imaging across rheumatoid arthritis models, while clarifying assay controls, competitive considerations, and the practical role of a Cy3-conjugated secondary antibody.

• SkQ1 and Muscle Atrophy in Ovarian Cancer

  2026-09-29

  This preprint tests whether mitochondrial reactive oxygen species, mitochondrial-linked apoptosis, or necroptosis drive skeletal muscle atrophy during metastatic ovarian cancer. Chronic SkQ1 treatment reduced late-stage mitochondrial hydrogen peroxide emission and caspase-9/-3 activity, yet did not preserve gastrocnemius muscle mass, challenging a simple causal model of cancer-associated atrophy.

• AZD8055 Protocol Guide for mTOR Inhibition

  2026-09-29

  AZD8055 is an ATP-competitive mTOR inhibitor for controlled studies of mTORC1 and mTORC2 signaling, cancer-cell proliferation, and metabolic responses. It is best suited to mechanistic preclinical workflows, not clinical efficacy testing or experiments requiring a water-soluble compound.

• MCL-1 Dependence in Breast Cancer

  2026-09-28

  This 2021 study shows that established breast tumors require MCL-1 primarily for its canonical anti-apoptotic function, rather than for an independent noncanonical activity. By combining acute genetic deletion, pharmacological inhibition, and BAX/BAK epistasis, the authors connect MCL-1 dependence to mitochondrial apoptosis and provide a framework for interpreting MCL-1-targeted therapies.

• TEAD2, Ferroptosis, and HCC: Study Insights

  2026-09-28

  This study combined public-database analyses with cell-based experiments to examine TEAD-family expression, clinical associations, and immune correlations in hepatocellular carcinoma (HCC). Its central experimental finding links reduced TEAD2 to iron accumulation, oxidative damage, and HCC cell death, providing a rationale for further testing of TEAD2 in ferroptosis and HCC research.

• WEHI-539: A Selective BCL-XL Inhibitor

  2026-09-27

  WEHI-539 is a potent, selective BCL-XL inhibitor for studying BCL-XL-dependent apoptosis and apoptotic resistance. Its mechanistic use is supported by biochemical and cellular findings, while glioblastoma combination evidence should be interpreted separately from the in vivo results obtained with a different BCL-2/BCL-XL inhibitor.

• A-1331852: BCL-XL Inhibitor Workflows

  2026-09-26

  A-1331852 helps researchers test whether cancer cells rely on BCL-XL to suppress mitochondrial apoptosis, with practical workflows for dose-response, target-dependence, and combination studies. The glioblastoma findings provide a useful framework for model selection while underscoring why BCL-XL inhibition should be interpreted alongside MCL-1 dependence and apoptotic competence.

• Toremifene for Breast Cancer: 20 Years of Evidence

  2026-09-25

  This review synthesizes two decades of clinical experience with toremifene, an oral selective estrogen receptor modulator used in postmenopausal patients with hormone receptor–positive breast cancer. It supports toremifene as an endocrine-therapy option while emphasizing that evidence has not established a clear safety advantage over tamoxifen and that patient context matters.

• FXR–KLF11 Signaling in Contrast-Induced Kidney Injury

  2026-09-25

  A 2026 preclinical study links FXR activation to direct transcriptional upregulation of KLF11, which restrains JAK2/STAT3 signaling and reduces contrast-induced acute kidney injury. The mouse and HK-2 cell findings support a defined protective pathway, while leaving dose, timing, and clinical efficacy questions for further study.

• EGCG Nanoparticles Strengthen FLASH Radiotherapy

  2026-09-24

  The study reports that functionalized, self-assembled EGCG nanoparticles (BENPs) can intensify FLASH-RT-associated oxidative stress and DNA damage in a 4T1-based tumor model, while also promoting antitumor immune changes. The findings support investigating nanoparticle radiosensitizers as a way to improve FLASH-RT efficacy, but remain preclinical and do not establish clinical benefit or a definitive mechanism.

• Sabutoclax Workflows for Apoptosis Assays

  2026-09-24

  Use Sabutoclax to test how simultaneous blockade of anti-apoptotic Bcl-2 family proteins shapes cancer-cell death—not just changes in metabolic viability. A paired, time-resolved workflow helps distinguish apoptosis from growth arrest and makes dose-response results more interpretable.

• CDCA and the FXR–KLF11 Axis: Beyond Metabolism

  2026-09-23

  Chenodeoxycholic Acid is best known as an FXR-active bile acid, but new preclinical evidence connects FXR signaling to a kidney-injury pathway. This article examines the FXR–KLF11–JAK2/STAT3 findings, their translational promise and limits, and practical considerations for using CDCA in mechanistic research.

8630 records 1/576 page Next 12345 下5页 Last page